Treatment of polycythemia vera: Use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age

Blood

Volumn 89, Issue 7, 1997, Pages 2319-2327

  Najean, Yves ^a   Rain, Jean Didier ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYUREA; PHOSPHORUS 32; PIPOBROMAN;

AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LIFE EXPECTANCY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; THROMBOCYTE COUNT; THROMBOEMBOLISM;

EID: 0031000705     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.7.2319     Document Type: Article

References (46)

1. Berglund S, Zettervall O: Incidence of polycythemia vera in a defined population. Eur J Haematol 48:20, 1992
2. Modan B: An epidemiological study of polycythemia vera. Blood 26:657, 1965
3. Berk PD, Wasserman LR, Fruchtman SM, Goldberg J: Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group, in polycythemia vera and the myeloproliferative disorders, in Wasserman LR, Berk PD, Berlin NI (eds): Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA, Saunders, 1995, p 166
4. Modan B, Lilienfeld AH: Polycythemia vera and leukemia: The role of radiation treatment. Medicine 44:305, 1965
5. Landaw SA: Acute leukemia in polycythemia vera. Semin Hematol 23:156, 1986
6. Benson AB, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K: Oncologists reluctance to accrue patients onto clinical trials. J Clin Oncol 9:2067, 1991
7. Lantos J: Informed consent: The whole truth for patients? Cancer 72:2811, 1993
8. Williams CJ, Zwitter M: Informed consent in European multicentre randomized clinical trials. Are patients really informed? Eur J Cancer 30A:907, 1994
9. Tobias JS, Houghton J: Is informed consent essential for all chemotherapy studies? Eur J Cancer 30A:897, 1994
10. Najean Y, Rain JD, for the French study group of polycythemias: Treatment of polycythemia vera. The use of hydroxyurea and pipobroman in 265 patients aged less than 65 years. Blood (in press)
11. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y: Interpretation of measured cell mass and plasma volume, expert panel on radio-nuclides of the International Conseil for Standardization in Haematology. Br J Haematol 89:748, 1995
12. Westwood N, Dudley JM, Sawyer B, Messinesy M, Pearson TC: Primary polycythemia, diagnosis by non-conventional positive criteria: Eur J Haematol 51:228, 1993
13. Emerson JD, Colditz GA: Use of statistical analysis in the New England Journal of Medicine. N Engl J Med 309:709, 1983
14. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35:1, 1977
15. Raghavan D: Adjuvant systemic therapy of prostate cancer. Semin Oncol 22:633, 1995
16. 32P in the treatment of polycythemia vera. Nouv Rev Fr Hematol 36:189, 1994
17. Institut National de la Santé et de la Recherche Médicale: Statistique de mortalité en France pour 1990. Med Sci 8:863, 1992
18. Terystne WE, Meuwinen OJ, Hagemeiger R, Michels JJ: Multiple myeloma in spent phase PV. Am J Clin Pathol 94:786, 1990
19. Anl C, Schneider W: The role of low dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 64:1812, 1989
20. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594, 1993
21. Pisani P, Parkin DM, Ferlay J: Estimates of the worldwide mortality from 18 major cancers in 1985. Int J Cancer 55:891, 1993
22. Najean Y, Arrago JP, Rain JD, Dresch C: The "spent" phase of polycythemia vera. Br J Haematol 56:163, 1974
23. Ward HP, Block MH: The natural history of agnogenic myeloid metaplasia and a critical evaluation of its relationship with the myeloid proliferative disorders. Medicine 50:357, 1971
24. Najean Y, Dresch C, Rain JD: The very long term course of polycythemia: A complement to the previously published data of the Polycythemia Vera Study Group. Br J Haematol 86:233, 1994
25. Fruchtman SM, Wasserman LR: Therapeutic recommendations for polycythemia vera, in Wasserman LR, Berk PD, Berlin NI (eds): Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA, Saunders, 1995, p 337
26. Haanen C, Mathe G: Treatment of polycythemia vera by radio-phosphorus or busulphan: A randomized trial. Br J Cancer 44:75, 1981
27. Messinezy M, Pearson TC, Prochazka A, Wheterley-Mein G: Treatment of proliferative polycythemia by venesection and low-dose busulphan. Br J Haematol 61:657, 1985
28. Bilgrani S, Greenberg BR: Polycythemia rubra vera. Semin Oncol 22:307, 1995
29. Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H: Leukemic transformation of polycythemia vera and essential thrombocythemia associated with an alkylating agent. Cancer 75:471, 1995
30. Brandt L, Anderson H: Survival and risk of leukemia in polycythemia vera and essential thrombocythemia treated with oral radiophosphorus. Eur J Haematol 51:21, 1995
31. Schafer AI: Bleeding and thrombosis in the myelo-proliferative disorders. Blood 64:1, 1984
32. 32P. Blood 32:356, 1968
33. Lawrence JH, Winchell HS, Donald WG: Leukemia in polycythemia vera: Relationship to splenic myeloid metaplasia and therapeutic radiation dose. Ann Intern Med 70:763, 1967
34. Berger R, Bernheim A, Flandrin G, Dresch C, Najean Y: Cytogenetic studies on acute non lymphocytic leukemias following polycythemia vera. Cancer Genet Cytogenet 11:441, 1984
35. 32P between 1969 and 1980. Semin Hematol (in press)
36. 32P treated patients with polycythemia vera and chronic lymphocytic leukemia. J Lab Clin Med 64:560, 1964
37. Pedersen-Bjergaard U: Radiotherapy and chemotherapy induced myelodysplasia and acute myeloid leukemia. Leuk Res 16:61, 1992
38. Rohatiner A: Myelodysplasia and acute myelogenous leukemia after myelo-ablative therapy with autologous stem-cell transplantation. J Clin Oncol 12:2521, 1994
39. Nand S, Messmore H, Fisher SG, Bird ML, Schulz W, Fisher RI: Leukemic transformation in polycythemia vera: Analysis of risk factors. Am J Hematol 34:32, 1990
40. Socie G, Henry-Amar M: Malignant tumor occurring after treatment of aplastic anemia. N Engl J Med 329:1152, 1993
41. Mauch PM, Kalisk LA, Marcus TC: Second malignancia for laparotomy staged IA-IIIB Hodgkin's disease. Blood 87:3625, 1996
42. Silverstein MN: Post-polycythemia myeloid metaplasia. Arch Intern Med 134:113, 1974
43. Castro-Malaspino H, Rabellino EM, Yen A, Nachman RL, Moore MAS: Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 57:781, 1981
44. Van XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, Mac Niece IK: A model of myelo-fibrosis and osteo-sclerosis in mice induced by over-expressing thrombopoietic. Blood 82:402, 1996
45. Ulrich TR, Del Castillo J, Senaldi G: Systemic hematologic effects of PEG recombinant-human MGDF-induced megakaryocyte hyperplasia in mice. Blood 87:5006, 1996
46. Silverstein MN and the Anagrelide Study Group: Anagrelide, a therapy for thrombocythemic states. Am J Med 92:69, 1992